Fig. 1 · Structure

Documents & Downloads

Ibuprofen

Cat. No. A10461 CAS 15687-27-1

COX-1 inhibitor

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) targeting COX-1 with an IC50 of 13 μM.

In Stock

Publications for Ibuprofen

3 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  3. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In murine COX-2, structural analysis places the ibuprofen carboxylate at Arg-120 and Tyr-355 in the substrate channel. In a corresponding enzyme assay, 100 μM racemic ibuprofen decreased wild-type arachidonic-acid oxygenation by 40%, whereas R120A and Y355F were not inhibited under the same conditions. This is a single-concentration result, not an IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
COX-1 13 μM
COX-2 370 μM

Cellular Effect

Cell Line Activity Value Description Reference
Bel-7402 IC50 > 100 μM Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay [PMID: 28301815]
Bel7402/5-FU IC50 > 100 μM Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay [PMID: 28301815]
BGC-823 IC50 > 50 μM Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay [PMID: 33799070]
Caco-2 IC50 > 50 μM Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay [PMID: 33799070]
CHO IC50 200 μM Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA [PMID: 20503989]
CHO IC50 200 μM Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA [PMID: 21873070]
COS-7 IC50 > 1000 μM Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 32527536]
HCT-116 IC50 448 μM Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay [PMID: 20171760]
HCT-15 IC50 > 1000 μM Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 32527536]
HT-29 IC50 > 50 μM Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 26750401]
HT-29 IC50 > 50 μM Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 26750401]
HT-29 IC50 > 50 μM Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 26750401]
HT-29 IC50 552 μM Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay [PMID: 20171760]
Huh-7 IC50 37.2 μM Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay [PMID: 26810835]
K562 IC50 > 1000 μM Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 32527536]
L02 IC50 > 100 μM Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay [PMID: 28301815]
MCF7 IC50 > 50 μM Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay [PMID: 35468536]
MCF7 IC50 > 50 μM Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay [PMID: 33799070]
MCF7 IC50 92.14 μM Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 32527536]
MDA-MB-231 IC50 > 50 μM Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 26750401]<

20 records · Scroll to view more

Ibuprofen Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Ibuprofen from 3 published references.

Ibuprofen In Vitro Studies

Racemic ibuprofen inhibited collagen-stimulated thromboxane B2 formation in human platelets, with IC50 values of 50 ± 27 μM in platelet-rich plasma and 0.3 ± 0.1 μM in washed platelets (mean ± s.e. mean; 3–6 experiments per group). The matrix dependence limits transfer of these values to other assays. S(+)-ibuprofen was more potent than the racemate, while R(−)-ibuprofen was less potent. [2]

Ibuprofen binding geometry in murine COX-2

Biochemical assay · Purified wild-type murine COX-2; X-ray crystal structure [1]

The structure places the ibuprofen carboxylate in a salt bridge with Arg-120 and a hydrogen bond with Tyr-355 at the cyclooxygenase-channel entrance. The reported refined model contains S-ibuprofen in both monomers; this record does not infer a quantitative enantiomer affinity ratio.

Literature-Reported Treatment Conditions

Treatment concentration
Five-fold molar excess of racemic (R/S)-ibuprofen relative to reconstituted enzyme
Exposure duration
30 min on ice before crystallization
Method
X-ray crystallography
Reported limits
Supplier, lot and enantiomeric assay of ibuprofen are not specified in the acquired main manuscript; Supplementary Figures 1–3 and tables were not retrieved.
Methods and source locations

Compound reported in the paper: Ibuprofen; Compound label in the paper: Racemic (R/S)-ibuprofen used for crystallization

Binding geometry in this murine protein crystal; no human potency or therapeutic dose extrapolation.

Sections 2.1–2.2 and 3.1; Figure 1 and caption; section 4 final paragraph

Wild-type and mutant COX-2 inhibition by racemic ibuprofen

Biochemical assay · Purified wild-type, R120A and Y355F murine COX-2; arachidonic-acid oxygenation [1]

At 100 μM racemic ibuprofen, wild-type enzyme activity decreased by 40% as reported in the Results. R120A and Y355F were not inhibited under the same assay conditions. Each construct was compared with its own no-ibuprofen control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wild-type COX-2 arachidonic-acid oxygenation relative to no-ibuprofen controlActivity decrease 40%[1]
R120A and Y355F COX-2 arachidonic-acid oxygenationQualitative result Neither mutant was inhibited under the tested conditions[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM (R/S)-ibuprofen during preincubation and in the assay; 100 μM arachidonic acid substrate
Exposure duration
30 min on ice before assay; residual activity assayed at 37°C
Method
Clark-type oxygen electrode; 5 μg enzyme in 3 mL containing 100 mM Tris pH 8, 1 mM phenol and 5 μM Fe3+-PPIX
Reported limits
Ibuprofen stock solvent and supplier are not specified in the acquired main manuscript; precise reaction readout duration and error-bar definition are not supplied in Figure 2 caption.
Methods and source locations

Compound reported in the paper: Ibuprofen; Compound label in the paper: Racemic (R/S)-ibuprofen

A single-concentration murine enzyme comparison; 100 μM is an assay concentration, not an IC50 or an animal dose.

Section 2.3; section 3.2 first paragraph; Figure 2 and caption

Wild-type COX-2 arachidonic-acid oxygenation relative to no-ibuprofen control: Oxygen-electrode assay; reactions repeated in triplicate (replication type not further specified). — Section 3.2 first paragraph; Figure 2 and caption

R120A and Y355F COX-2 arachidonic-acid oxygenation: Same assay and concentration as wild type; no exact mutant bar heights inferred. — Section 3.2 first paragraph; Figure 2 and caption

Matrix-dependent inhibition of human platelet responses

Cell-based study · Human platelet-rich plasma and washed platelets; collagen-stimulated aggregation and thromboxane B2 formation [2]

Racemic ibuprofen inhibited collagen-induced aggregation and thromboxane B2 formation. Its IC50 values were much lower in washed platelets than in platelet-rich plasma. The S(+)-enantiomer was more potent and R(−)-ibuprofen less potent in both matrices. These are cellular endpoints, not purified-enzyme binding constants.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Collagen-stimulated thromboxane B2 formation in platelet-rich plasmaIC50 50 ± 27 μM[2]
Collagen-stimulated thromboxane B2 formation in washed plateletsIC50 0.3 ± 0.1 μM[2]
Collagen-stimulated aggregation in platelet-rich plasmaIC50 134 ± 63 μM[2]
Collagen-stimulated aggregation in washed plateletsIC50 1.3 ± 0.3 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response experiments; collagen 2.5 μg/mL for the adopted Tables 1–2
Exposure duration
Ibuprofen added at beginning of an 8-min preincubation; thromboxane sampling described at 8 min in the aggregation assay
Method
Photometric aggregation at 37°C; supernatant thromboxane B2 measured by radioimmunoassay
Vehicle
Ibuprofen dissolved in 50 mM Tris buffer, pH 7.4; final solvent concentrations reported not to affect the assay
Reported limits
Individual concentration-series points are graphical rather than tabulated. Tables report 3–6 experiments per group, without a per-endpoint donor count or explicit biological/technical replication allocation.
Methods and source locations

Compound reported in the paper: Ibuprofen; Compound label in the paper: Racemic ibuprofen; S(+)- and R(−)-ibuprofen comparators

In vitro human platelet response; matrix-specific IC50 values must not be used as a universal COX potency or dosing recommendation.

Pages 236–238: platelet and washed-platelet methods, reagents, statistics, platelet results; page 237 Tables 1–2 and Figure 1

Collagen-stimulated thromboxane B2 formation in platelet-rich plasma: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 1 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response

Collagen-stimulated thromboxane B2 formation in washed platelets: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 2 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response

Collagen-stimulated aggregation in platelet-rich plasma: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 1 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response

Collagen-stimulated aggregation in washed platelets: Mean ± s.e. mean of 3–6 experiments in each group, as stated in table footnotes; no-ibuprofen stimulated control response; photometric aggregation or thromboxane B2 radioimmunoassay. — Page 237, Table 2 (rac-ibuprofen row); platelet methods pages 236–237; Figure 1 for thromboxane concentration-response

Ibuprofen In Vivo Studies

In male Sprague–Dawley rats with carrageenan-evoked thermal hyperalgesia, a single 50 mg/kg intraperitoneal dose of ibuprofen, given 30 min before or 165 min after carrageenan, attenuated the behavioral response (n = 6 per group). This was an ibuprofen-only comparator experiment; molecular effects measured in separate paeonol groups cannot be attributed to ibuprofen. [3]

Ibuprofen comparator in rat thermal hyperalgesia

Animal study · Male Sprague–Dawley rats, 8–9 weeks, 200–250 g; carrageenan-evoked paw thermal hyperalgesia [3]

Ibuprofen given alone at 50 mg/kg intraperitoneally before or after carrageenan attenuated thermal hyperalgesia in this experiment. Paw-withdrawal latency was the endpoint; no exact effect size is estimated from the plot. This ibuprofen comparator does not establish the cytokine, nitric-oxide or protein-expression effects tested separately with paeonol.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ibuprofen pretreatment
50 mg/kg
DMSO-treated/carrageenan-injected group; DMSO-treated/saline-injected control and contralateral uninjected paw also assessedAttenuated carrageenan-evoked thermal hyperalgesia, assessed as increased paw-withdrawal latency. Exact numerical effect sizes are not tabulated and are not inferred from Figure 1.[3]
Ibuprofen post-treatment
50 mg/kg
DMSO-treated/carrageenan-injected group; DMSO-treated/saline-injected control and contralateral uninjected paw also assessedAttenuated carrageenan-evoked thermal hyperalgesia, assessed as increased paw-withdrawal latency. Exact numerical effect sizes are not tabulated and are not inferred from Figure 1.[3]
Ibuprofen pretreatment
Model: Male Sprague–Dawley rats; n = 6 per group
Treatment course: 30 min before carrageenan
Reported limits: Ibuprofen-specific solvent and stereochemistry are not separately specified; group-level raw data not retrieved.
Ibuprofen post-treatment
Model: Male Sprague–Dawley rats; n = 6 per group
Treatment course: 165 min after carrageenan
Reported limits: Ibuprofen-specific solvent and stereochemistry are not separately specified; group-level raw data not retrieved.
Methods and source locations

Compound reported in the paper: Ibuprofen; Compound label in the paper: Ibuprofen (Sigma); stereochemistry unspecified

A single-dose rodent behavioral comparator in a paeonol paper; no clinical efficacy, chronic dosing or ibuprofen molecular-mechanism claim.

Methods: Animals; Induction and assessment of carrageenan-evoked thermal hyperalgesia; Drug treatment; Statistical analysis. Results: first subsection; Figure 1a–b and caption

Ibuprofen pretreatment · Drug treatment and hyperalgesia methods; Figure 1a and caption; first Results subsection

Ibuprofen post-treatment · Drug treatment and hyperalgesia methods; Figure 1b and caption; first Results subsection

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 15687-27-1
Applications COX-1 inhibitor
Formula C13H18O2
Molecular Weight 206.3
Synonyms Genpril; Brufen; Nurofen; Motrin; Ibren; Ibuprohm; Advil
SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 40 mg/mL (193.9 mM)
Water Insoluble
Ethanol 40 mg/mL (193.9 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
19 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ibuprofen Research References

  1. [1] Benjamin J Orlando, Michael J Lucido, Michael G Malkowski. The structure of ibuprofen bound to cyclooxygenase-2. Journal of Structural Biology (2015). PMID: 25463020 DOI: 10.1016/j.jsb.2014.11.005 Source material
  2. [2] M Villanueva, R Heckenberger, H Strobach, et al. Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. British Journal of Clinical Pharmacology (1993). PMID: 8385973 DOI: 10.1111/j.1365-2125.1993.tb05690.x Source material
  3. [3] Tz-Chong Chou. Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. British Journal of Pharmacology (2003). PMID: 12871833 DOI: 10.1038/sj.bjp.0705360 Source material

Publications

3 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  3. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Added to your cart

View Cart Checkout
Loading...